Bluejay Diagnostics Announces Insider-Funded Private Stock Placement

Bluejay Diagnostics ( (BJDX) ) has shared an announcement.

On March 14, 2024, Bluejay Diagnostics, Inc. entered into a securities purchase agreement with several board members and executives, including its president and CEO, to sell 62,500 shares of common stock at $2.00 per share in a private placement. The transaction, which closed on March 17, 2026 and raised $125,000 in gross proceeds, was conducted under exemptions from Securities Act registration, involved only accredited investors, and did not include registration rights, underscoring insider support for the company while resulting in a modest equity dilution for existing shareholders.

The most recent analyst rating on (BJDX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Bluejay Diagnostics stock, see the BJDX Stock Forecast page.

Spark’s Take on BJDX Stock

According to Spark, TipRanks’ AI Analyst, BJDX is a Neutral.

The score is held down primarily by weak financial performance (minimal revenue, ongoing losses, and continued cash burn) and a bearish technical setup (below major moving averages with negative MACD). Positive corporate progress on the Symphony IL-6 program and manufacturing readiness provides some offset, but valuation offers limited support given persistent losses and no dividend.

To see Spark’s full report on BJDX stock, click here.

More about Bluejay Diagnostics

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on developing and commercializing diagnostic solutions, with its business centered around its publicly traded common stock and access to capital markets to fund operations and growth initiatives.

Average Trading Volume: 237,338

Technical Sentiment Signal: Sell

Current Market Cap: $1.9M

For detailed information about BJDX stock, go to TipRanks’ Stock Analysis page.